Abstract: A computer-implemented method according to one embodiment includes collecting device information from at least a first device, and receiving, from the first device, a first request to attach to a first base station. In response to receiving the first request, it is determined whether a signal broadcasted from the first base station includes public land mobile network (PLMN) information of a first type of telecommunication signal. In response to a determination that the signal broadcasted from the first base station includes the PLMN information, a second request is sent to a core network to connect the first device to a node associated with the first type of telecommunication signal of the first base station. In response to receiving an indication that the first device is authorized to connect, a connection is allowed to be established between the first device and the node associated with the first type of telecommunication signal.

Abstract: Provided herein is a crystallized ternary structure of aldose reductase (AR) bound to NADPH and ?-glutamyl-S-(1,2-dicarboxyethyl)cysteinylglycine (DCEG). Also provided are specific inhibitors of glutathione-aldehyde binding to aldose reductase which are designed via at least computer modeling of the ternary AR:NADPH:DCEG structure and methods of designing and of screening the inhibitors for inhibition of glutathione-aldehyde binding to aldose reductase. In addition methods of treating a pathophysiological state or symptoms thereof resulting from aldose reductase-mediated signaling in a cytotoxic pathway using a small interfering RNA (siRNA) or the designed inhibitors.

Abstract: Embodiments of the invention include methods and compositions involving aldose reductase inhibitors for the treatment of sepsis and autoimmune diseases, including Type I diabetes and rheumatoid arthritis. The invention also pertains to preventing the loss of cardiac muscle contractibility.

Abstract: Embodiments of the invention include methods and compositions for the inhibition of Aldose Reductase by nitric oxide. Certain embodiments of the invention include the induction of nitric oxide by administration of a nitric oxide donor, nitric oxide precursor, inhibitor of a nitric oxide synthase inhibitor, and/or an activator of nitric oxide synthase. Methods may include the treatment of various disease states by inhibiting Aldose Reductase.

Abstract: Provided herein is a crystallized ternary structure of aldose reductase (AR) bound to NADPH and ?-glutamyl-S-(1,2-dicarboxyethyl)cysteinylglycine (DCEG). Also provided are specific inhibitors of glutathione-aldehyde binding to aldose reductase which are designed via at least computer modeling of the ternary AR:NADPH:DCEG structure and methods of designing and of screening the inhibitors for inhibition of glutathione-aldehyde binding to aldose reductase.